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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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Etiology and relevance 
Bovine Anaplasmosis (BA), an arthropod-borne disease of ruminants, is predominantly caused by Anaplasma 
marginale, an obligate intraerythrocytic parasite in the genus Anaplasma belonging to the family 
Anaplasmataceae of the order Rickettsiales. The organisms in this order were recently reclassified based on 
genetic analysis of 16S rRNA, groELS and surface protein genes. The genus Anaplasma includes three species 
that can infect ruminants, A. marginale, A. centrale and A. ovis. A. marginale and A. centrale infect cattle, but 
differ in morphology, virulence and geographical distribution. 
A. marginale was discovered and first described in 1910 by Arnold Theiler in South Africa, who shortly after 
noted also a less pathogenic strain which he called A.centrale: this second discovery has had a tremendous 
impact in the control of bovine anaplasmosis as he could demonstrate its ability to protect inoculated cattle 
against A. marginale challenge. The vaccine he then developed is still used to date, with the same strain for 
bovine anaplasmosis.  
 
Epidemiology and transmission 
Anaplasmosis has a worldwide distribution particularly in tropical and subtropical regions; it is also seen in some 
temperate areas. The disease is endemic in Africa, South and Central America, southern Europe, the Far and 
Middle East, India, Russia, and Australia.  
While A. marginale and bovine anaplasmosis affects cattle and water buffaloes in Asia, several wild ungulate 
species are also affected and play an important role in the disease epidemiology. Bos indicus cattle breeds 
appear to possess a greater resistance to A. marginale infection than Bos taurus breeds, but variation in 
resistance of individuals within breeds of both species may well occur.  
Anaplasma species are transmitted either mechanically or biologically by arthropod vectors. In general, tick 
vectors of A. marginale include Boophilus spp., selected Dermacentor spp., Ixodes ricinus and Rhipicephalus spp., 
while Amblyomma spp. do not appear to transmit A. marginale. Reviews based on careful study of reported 
transmission experiments list up to 20 of these different ticks as capable of transmitting A. marginale. 
Intrastadial or transstadial transmission is the usual mode, even in the one-host Rhipicephalus species. Male 
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Due to the fact that A. marginale primarily infects erythrocytes, anaemia, jaundice and sudden death are 
characteristic signs of anaplasmosis. Other symptoms of bovine anaplasmosis include fever, lethargy, weight 
loss, lowered milk production, and abortion. It is often fatal in older cattle if they are not treated early 
The severity of bovine anaplasmosis increases with age: calves under six months of age rarely become ill; 
between 6-12 months they usually develop mild disease, which is more acute at 1-2 years old; finally, adults 
over two years old suffer acute and often fatal disease. 
Cattle that recover from acute disease usually remain persistently infected showing cyclical rises in rickettsemia, 
which trigger the generation of antigenic variants that escape immune control and multiply rapidly, before they 
stimulate a variant-specific immune response that brings the infection under control again. Due to this 
consistent stimulation, persistently infected cattle maintain a strong immune response against A. marginale, and 
are protected from disease when subsequently challenged with the homologous A. marginale strain though, 
sadly, they act as reservoirs of infection for naïve cattle. 
 
Incidence / Prevalence and economic impact 
Though known to be very prevalent in areas where the disease is endemic, very little prevalence data exist for 
certain regions. Bovine anaplasmosis has a serious economic impact on the cattle industry of endemic areas, and 
more specifically in the target countries, essentially due to  animal mortality, morbidity and reduced 
productivity, cost of acaricides and other treatment, including chemotherapy and immunisation where 
applicable. In most countries economic costs directly associated to Anaplasmosis are included in overall costs of 
tick borne diseases.    Only in Eastern and Southern Africa, the only regions of the African continent where data 
exist, there are more than 80 million animals that are at risk of Anaplasmosis with costs for countries like 
Tanzania estimated at 48 million USD annually. In India, Anaplasmosis is considered as one of the top 10 
economically important diseases affecting ruminants.  
 
Diagnostics 
Microscopic examination of blood or organ smears is the most common method of identifying Anaplasma in 
clinically affected animals. Several serological tests are also employed in epidemiological studies: complement 
fixation (CF) test, capillary agglutination assay, card agglutination test (CAT), indirect fluorescent antibody (IFA) 
test, as well as various ELISA such as a cELISA, indirect ELISA and dot ELISA. The two serological tests currently 
preferred for identifying infected animals are the cELISA and the CAT. PCR have also been developed that are 
capable of detecting the presence of low-level infection in carrier cattle and tick vectors. 
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The control of Bovine Anaplasmosis varies according to regions and their level of endemicity, with major 
components being the maintenance of A. marginale-free herd, vaccination, tick control, treatment with 
tetracycline during acute disease and administration of low-level tetracycline for prevention of clinical disease.  
Tick control is practised in many parts of affected countries through use of acaricides or improved animal 
management. Acaricides have however been linked to several tick resistance cases, thus compromising ther use. 
Maintenance of a stable disease situation by strategically allowing natural exposure of calves to tick-borne 
diseases, including anaplasmosis, is often practised in Southern and Eastern Africa.  
Treatment or chemotherapy with antibiotics is the most widely used control measure for Bovine anaplasmosis, 
with Tetracycline antibiotics being by far the predominant treatment method.   
Vaccination is the control method used since the description of bovine anaplasmosis in 1911 in South Africa. Live 
vaccines based on the Theiler A. centrale strain are used in several countries; they yields partial protection 
against challenge with virulent A. marginale.  
 
Vaccination and vaccination strategies 
Even though inactivated vaccines have been used in the USA, and most of them discontinued since the 1990s, 
the live vaccine based on the A. centrale from Arnold Theiler in 1911 is still used to date in all countries using live 
vaccine.  Such vaccine, now delivered in a frozen form, is used to date in South Africa, Israel, Latin American 
countries and Australia, where it forms part of a multivalent vaccine, and supplied chilled. 
Both killed and live vaccines rely on erythrocyte-derived antigen sources. None of the two vaccine forms prevent 
cattle from becoming persistently infected with A. marginale or becoming reservoirs of infections. 
The development of an effective bovine anaplasmosis vaccine preventing the infection is complicated by the 
increasing numbers of A. marginale field strains that occur in a given geographical area. While research carried 
out in the last two decades has contributed greatly to our knowledge of the antigenic composition of A. 
marginale, it has not, as yet, led the development of novel vaccines using molecular technologies. 
Live blood Anaplasmosis vaccine has several disadvantages including: lack of cross protection with several 
strains of A. marginale, residual virulence especially when administered in adult animals, challenges linked with 
the cold chain as the current vaccines used in Africa are frozen and have to be maintained at temperature below 
0°C during transportation, a condition difficult to meet in Africa. There is also the risk of transmitting other 
diseases through the blood.   
Of the promising opportunities for new generation vaccines, is proteomic and genomic work at at the University 
of Washington (USA) that has permitted to identify new proteins within the outer membrane immunogen in 
addition to the well-characterized Major Surface Proteins (MSP1–MSP5), which hold promises for potential 
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vaccine; but they still have to be further selected and evaluated in cattle studies. Cell culture systems also, by 
propagating A. marginale in a continuous tick cell line derived from embryonic Ixodes scapularis, have also 
yielded less infective vaccine antigens. A group in The Pirbright Institute, (UK) has published this year a paper on 
their successful cultivation of A. centrale in tick cells. There will be a need to assess the vaccine characteristics of 
this cell derived A. centrale in challenge studies.  
 
The future of Bovine Anaplasmosis vaccines and vaccination  
Given the difficulties in producing and transporting the current live attenuated A. centrale vaccine, only South 
Africa produces and use the vaccination approach to the control of BA, and to a lesser extend Zambia. A number 
of approaches could be considered in order to improve the availability and use of vaccination in the control of 
BA. 
The current live Theiler A. centrale vaccine has serious limitations that would prevent its use in more countries. 
With limited research and work toward the development of a vaccine over the past few years, and the lack of 
funds toward such research, a new generation vaccine may be a long way away. There may be a possibility of 
evaluating in target animal the candidates selected by the Washington State University group. These candidate 
vaccines are likely to lead to a potentially very efficacious and safe vaccine.  
The “quick win” would be the use of the newly established cell culture system for A.centrale vaccine strain 
developed at The Pirbright Institute, which could allow the production of a less risky cell-based vaccine. 
Additionally, work on lyophilisation of the vaccine could be pursued. A cell-based lyophilised bovine 
anaplasmosis vaccine would then have a major impact on in the control of bovine anaplasmosis. 
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Bovine Anaplasmosis is an arthropod-borne disease of ruminants, first described by Arnold Theiler in South 
Africa first described the disease in 1910, which is caused predominantly by Anaplasma marginale, and is 
generally characterized by fever, progressive anaemia and icterus. 
The pathogen is an obligated intraerythrocytic parasites in the genus Anaplasma belonging to the family 
Anaplasmataceae of the order Rickettsiales 
Anaplasma species were originally regarded as protozoan parasites, but further research showed they had no 
significant attributes to justify this description. Further to comprehensive genetic analyses of the 16s rRNA, 
groESL and surface protein genes, the genus Anaplasma is now reclassified as one of four distinct genera in the 
family Anaplasmataceae, alongside Ehrlichia, Wolbachia and Neorickettsia. The organisms within this family are 
Gram-negative, obligate intracellular bacteria vectored primarily by ticks. A unique feature of these organisms is 
that they reside and replicate within parasitophorous vacuoles in the host cell cytoplasm of their tick and 
vertebrate hosts [19].  
After the identification by A. marginale in 1910, Arnold Theiler identified and described a less pathogenic strain 
which he called A.centrale and which turned out to have a tremendous impact in the control of bovine 
anaplasmosis to this day. He based the distinction between A. marginale and A. centrale (Fig. 1) on: 
• the different position taken up by the two parasites within the erythrocyte,  
• the presence of slightly smaller sized organisms in A. centrale infections,  
• the lower virulence of A. centrale, and  
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Figure 1: Blood smears of A. marginale (left) and A. centrale (right). [35] 
 
While A. marginale is the main pathogen causing Bovine anaplasmosis, Anaplasma centrale is capable of 
producing a moderate degree of anaemia, but clinical outbreaks in the field are extremely rare. New species of 
Anaplasma, A. phagocytophilum and A. bovis, with a primary reservoir in rodents, have been reported to infect 
cattle, but do not cause clinical disease [20][35]. 
A. marginale has a small genome estimated at 1.2 to 1.6 Mb. There are six major surface proteins (MSPs) that 
have been identified on A. marginale derived from bovine erythrocytes and found to be conserved on tick- and 
cell culture-derived organisms [18]: MSP1a, MSP1b, MSP2, MSP3, MSP4 and MSP5. Three of these MSPs, namely 
MSP1a, MSP4 and MSP5, are from single genes and do not vary antigenically during the multiplication of the 
bacterium,  while the other three, MSP1b, MSP2 and MSP3, are from multigene families and may vary 
antigenically, most notably in persistently infected cattle [21]. However, recent results demonstrated selection of 
MSP2 sequence variants in persistently infected ticks.  
Due to the fact that MSPs are the most abundant, immunogenic and highly expressed, they have significance in 
vaccine research and have been part of several new generation vaccine studies. MSP1a, MSP1b and MSP2 have 
been shown to be adhesins involved in A.marginale interaction with cattle and ticks, with MSP1a having been 
shown to be the adhesin that binds erythrocytes, tick cell extracts and the gut cells of tick vectors [8].  MSP4 and 
MSP5 are both encoded by single-copy genes, and are highly conserved. As such they are useful for phylogenetic 
analysis [9] and diagnostics, with MSP5 used for a commercial diagnostic ELISA [43] 
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Susceptible animal species  
A. marginale and bovine anaplasmosis affects only ruminants, domestic and wild ruminants. In Asia the disease 
is a problem in cattle and water buffaloes.   
It has long been known that Anaplasma spp. can infect certain wild ungulate species, but there is mounting 
evidence that a wide host range may be involved, e.g. the giraffe, African buffalo, eland, greater kudu, nyala (T. 
angasii), waterbuck, etc. Anaplasma infections are readily maintained in cattle populations. The importance, if 
any, of wild ungulates as a reservoir for the transmission of Anaplasma spp. to cattle is unknown. [35] 
 
Breed differences in susceptibility 
Several studies have been carried out to determine if there is a difference in susceptibility for A. marginale 
infection between local African and Asian breeds (Bos indicus), European breeds (Bos taurus) and their crosses. 
B. indicus have been shown to be susceptible to anaplasmosis and may also develop clinical symptoms. Under 
experimental inoculation B. taurus, B. indicus and their crosses were equally susceptible to A. marginale and 
developed similar responses in packed cell volume (PCV)-depression and maximum rickettsemia detected 
microscopically [6]. Bock et al. [6] showed that 50 % of B. indicus needed treatment to recover in contrast to 100 % 
of the pure B. taurus. When comparing B. indicus and crosses after artificial infection with A. marginale via R. 
microplus there were no significant breed differences. 
 
Distribution 
Anaplasmosis has a worldwide distribution particularly in tropical and subtropical regions, it also seen in some 
temperate areas. The disease is endemic in Africa including Egypt, South and Central America, southern Europe, 
the Far and Middle East, India, Russia, and Australia. See Figure 2.  
Clinical anaplasmosis was first described in Indian cattle from the State of Odisha in 1963. Subsequently, A. 
marginale infection was detected in livestock of Uttar Pradesh, Punjab, Haryana, Tamil Nadu, Karnataka, Jammu 
and from parts of north and central India. In recent times, anaplasmosis has been recorded in Jammu, 
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Figure 2: Global distribution of bovine anaplasmosis source: http://www.cabi.org/isc/datasheet/91734  
 
Vectors of Bovine anaplasmosis and Transmission 
A. marginale develops persistent infections in cattle and tick hosts. While erythrocytes appear to be the only site 
of infection in cattle, A. marginale undergoes a complex developmental cycle in ticks and transmission occurs via 
salivary glands during feeding. Many geographic isolates occur that vary in genotype, antigenic composition, 
morphology and infectivity for ticks. 
Anaplasma species are transmitted either mechanically or biologically by arthropod vectors. Various tick and 
haematophagous fly species are vectors of Anaplasma spp: Ixodid ticks are the principal biological vectors of 
anaplasmosis, but the argasid tick Ornithodoros savignyi, can also transmit A. marginale. [20]. Reviews based on 
careful study of reported transmission experiments list up to 20 different ticks as capable of transmitting A. 
marginale [20]. These are: Argas persicus, Ornithodoros lahorensis, Dermacentor albipictus, D. andersoni, D. 
hunteri, D. occidentalis, D. variabilis, Hyalomma excavatum, H. rufipes, Ixodes ricinus, I. scapularis, Rhipicephalus 
annulatus (formerly Boophilus annulatus), R. bursa, R. calcaratus, R. decoloratus, R. evertsi, R. microplus, R. 
sanguineus and R. simus. 
Rhipicephalus species are clearly important vectors of anaplasmosis in Africa and regions such as Australia, and 
Latin America, and some species of Dermacentor are efficient vectors in the USA [2]. 
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Based on the fact that the geographic distribution of R. (B.) decoloratus in southern Africa is virtually the same as 
the area where bovine anaplasmosis is endemic, this tick is regarded as the main vector of Anaplasma spp. See 









Figure 4: Schematic representation of the development cycle of A. marginale in cattle and ticks. (Source: 
20) 
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In South Africa, the role that specific ticks play in the transmission of the disease has not been extensively 
studied. The one-host tick B. decoloratus has been incriminated circumstantially as being the most important 
vector, simply because occurrence of the disease is thought to correlate with the distribution of this tick. 
However, four other tick species (B. microplus, R. simus, R. e. evertsi and H. m. rufipes) have been shown 
experimentally to be capable of transmitting the infection, and their distribution largely overlaps that of B. 
decoloratus. These ticks are therefore also considered to be involved in the epidemiology of anaplasmosis in 
South Africa. [35] 
The time required by feeding ticks to transmit the infection seems to vary between species. Adult D. andersoni 
have to feed at least six or seven days before transmission takes place, while adult R. simus may transmit the 
infection within 24 hours after infestation [37][35] 
Intrastadial or transstadial transmission is the usual mode, even in the one-host Rhipicephalus species. Male 
ticks may be particularly important as vectors; they can become persistently infected and serve as a reservoir for 
infection. Experimental demonstration of vector competence does not necessarily imply a role in transmission in 
the field. However, Rhipicephalus species are clearly important vectors of anaplasmosis in countries such as 
Australia and countries in Africa, and Latin America, and some species of Dermacentor are efficient vectors in 
the United States of America (USA).  
Mechanical transmission: At least 12 species of biting flies have been shown experimentally to have the 
potential of mechanically transmitting A. marginale, including stable flies (Stomoxys calicitrans), eight species of 
tabanids (Tabanidae – commonly called horse or deer flies) and three species of midges (Culicidae). [2] 
Transplacental transmission has been measured at around 15 % by Potgieter and Van Rensburg [36], and as such 




The most marked clinical signs of anaplasmosis are anaemia and jaundice, the latter occurring late in the 
disease. This is the result of the fact that A. marginale primarily infects erythrocytes, and as part of the host 
response, these infected cells - along with considerable numbers of uninfected erythrocytes - are then destroyed 
by the reticuloendothelial system, this resulting into anemia and icterus [35]. Haemoglobinaemia and 
haemoglobinuria are not present, and this may assist in the differential diagnosis of anaplasmosis from 
babesiosis, which is often endemic in the same regions.  
The severity of anaplasmosis is directly related to the age of the animal: in animals less than one year old it is 
usually subclinical; in yearlings and two-year-olds it is moderately severe; and in older cattle it is severe and 
often fatal. Differences in virulence between Anaplasma strains and the level and duration of the parasitaemia 
also play a role in the severity of the clinical manifestations. Generally, cases are presented for treatment when 
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the disease has advanced to the stage of the anaemic crisis. Anaemia is usually not clinically apparent until a loss 
of about 40 to 50 per cent of red blood cells has occurred. [35][42] 
After a natural prepatent period, which generally varies between 15 and 36 days (with an average of 26 days), 
although it may be as long as 100 days, peracute, acute or chronic anaplasmosis may follow: 
• Peracute anaplasmosis, rare and usually fatal, occurs most frequently in purebred animals and high-
producing dairy cows. Animals succumb within a few hours of the onset of clinical signs. In addition to 
anaemia, milk production ceases, and there is excessive salivation, rapid respiration, irrational behaviour 
and signs of nervousness 
• The acute form is essentially characterised by the pallor of mucous membranes, depression, 
inappetence, a decrease in milk production, general weakness, and a rapidly rising parasitaemia. In 
some animals, fever provides initial and persistent clinical evidence of anaplasmosis, but this is not 
consistent. The course of the acute disease is generally protracted and may last for two weeks or more 
before there is any evidence of improvement in the animal’s condition 
• Chronic anaplasmosis is manifested by slow recovery following acute disease, and it may persist for a 
period of between two weeks and three months. It is characterized by poor appetite, loss of weight and 
varying degrees of dehydration, anaemia and icterus which are usually milder than in the acute disease 
A. marginale infections may induce temporary infertility in bulls, anoestrus in heifers, and abortions and 
neonatal anaplasmosis following foetal infection. The mortality rate, particularly in adult cattle of exotic breeds, 
may exceed 50 per cent [35] 
Cattle that recover from acute disease usually remain persistently infected, often at microscopically 
undetectable levels (<107 rickettsia/ml). Throughout this persistent infection, they show cyclical rises in 
rickettsemia. These peaks in rickettsemia are believed to lead to the generation of antigenic variants, which 
escape immune control and multiply rapidly, before they stimulate a variant-specific immune response that 
brings the infection under control again. Due to this consistent stimulation, persistently infected cattle maintain 
a strong immune response against A. marginale, and are protected from disease when subsequently challenged 





A diagnosis of bovine anaplasmosis may be made tentatively based on geographic location, history, season, 
signalment and presenting clinical signs and/or necropsy findings observed in infected animals. 
However, microscopical identity of the agent in thin blood films stained with either Giemsa or proprietary stains 
is the traditional more accurate diagnostic method for clinical cases. In these smears, A. marginale organisms 
appear as dense, rounded, intraerythrocytic bodies approximately 0.3–1.0 μm in diameter situated on or near 
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the margin of the erythrocyte. A centrale is similar in appearance, but most of the organisms are situated toward 
the centre of the erythrocyte. It can be difficult to differentiate A. marginale from A. centrale in a stained smear, 
particularly with low levels of rickettsaemia. 
Table 1 shows the tests recommended by the OIE for the different purposes: to demonstrate population or 
individual freedom, confirmation of clinical cases, etc.  




Key: +++ = recommended method; ++ = suitable method; + = may be used in some situations, but cost, reliability, or 
other factors severely limits its application; – = not appropriate for this purpose. Although not all of the tests listed as 
category +++ or ++ have undergone formal validation, their routine nature and the fact that they have been used widely 
without dubious results, makes them acceptable. Agent id. = agent identification; CAT = card agglutination test; CFT = 
complement fixation test; ELISA = enzyme-linked immunosorbent assay; IFAT = indirect fluorescent antibody test; PCR = 
polymerase chain reaction 
 
The gold standard for the demonstration of A. marginale-free blood is the sub-inoculation of blood from the 
suspect animal into a splenectomized calf that is highly susceptible to infection [35][43]. If the donor is infected, A. 
marginale will be observed in smears from the splenectomized calf generally within 4 weeks, but this period 
may extend up to 8 weeks. However, this method is costly and raises welfare issues, as the splenectomized 
calves become very ill after sub-inoculation of infected blood and often have to be euthanized [43]. For these 
reasons, it would not be feasible to use sub-inoculation of splenectomized calves as the gold standard for the 
validation of assays. Thus, older tests have typically been validated using microscopic detection of A. marginale 
or comparison with other serology results, and newer ELISA tests have usually been validated using PCR 
methods that have not been formally validated themselves. 
 
Lateral flow assays have been, as in many tropical diseases a desired option, especially if they could help in 















Prevale ce of 
infection-
surveillance





examination - + - +++ - -
PCR - +++ - +++ - -
CAT - - - - + - +
ELISA +++ + +++ - +++ +++
IFAT + - - - ++ ++
CFT - - - - + -
Agent identifictaion 
DETECTION OF IMMUNE RESPONSE
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Canadian researchers from Canadian Food Inspection Agency have developed a lateral flow assay (LFA) for the 
rapid detection of bovine antibody to A. marginale [28]. The assay uses a recombinant peptide of MSP5 as the 
antigen and a monoclonal antibody specific for bovine IgG1 conjugated with colloidal gold beads for detection. 
Of the 114 samples that were selected based on positive identification of the organism in blood smears, all were 
positive by LFA, cELISA and semi-nested PCR (Se = 100% for all three tests). Samples from Canadian sources (n = 
524) were all negative on the cELISA using 30% inhibition as a cut-off and PCR (n = 40, randomly selected), but 
11 sera gave false-positive reactions on the LFA (Sp = 97.9%). Of 113 samples from non- Canadian herds in 
bovine anaplasmosis-endemic areas, 53 were positive on the cELISA and 50 were LFA positive. Using the cELISA 
as a reference, the sensitivity of the LFA would be estimated at 94% [28].  
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As stated earlier bovine anaplasmosis has a wide distribution and occurs in tropical and subtropical regions 
worldwide (approximately 40° N to 32° S), including South and Central America, the USA, southern Europe, 
Africa, Asia and Australia. 
Reporting of the disease however, as is the case for many endemic diseases in Africa and Asia, is very irregular 
and not necessarily representing the full picture. Since there is no evidence that the disease can be eradicated 
from infected countries, all countries having reported the disease at a certain stage can be considered 




1- Source: OIE.   
Data of outbreaks reported to the World Animal Health Organization [43] are shown in Tables 2 and 3.  Data are 
not always reliable, as many countries do not seem to report, or to be reporting consistently over time.   
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail.  Similar information but 
presented in a different manner can be seen in Annex 1.   
 
-   No information,      +   Present but quantitative data not known,  ?  Disease suspected 
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Table 2: ASIA- Number of Bovine Anaplasmosis outbreaks reported to the OIE between 2005-2015 (Numbers given 
only for the target countries) Source: OIE.        
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Asia 
Bangladesh   + + + + + + + +  
India 14 14 13 14 16 29 27 27 38 108  
Indonesia + + + + + + + + +   
Myanmar 
(Burma) 
0 0 0 0 4 3 5 0 3 23  
Nepal 2 2 0 0 0 4 3 4 0 0  




Table 3:  AFRICA- Number of Bovine Anaplasmosis outbreaks reported to the OIE between 2005-2015 
(Numbers given only for the target countries). Source: OIE.   
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
West Africa 
Mali 0 0 0 0 + 0 0 0 0 0  
Senegal 1 0 0 0 0 0 0 0 0 0  
East Africa 
Ethiopia + 0 + + + + + + 0 0  
Kenya 0 + 1 + + + + 2 + 5  
Rwanda 0 + + + + + + + + +  
Tanzania 30 35 332 114 69 61 45 19 32 45  
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2- Source: AU-IBAR. 
For the African continent, the number of outbreaks reported to AU-IBAR is included in the Pan African Animal 
Resources Year Book. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=) 
and can be seen for the countries of interest in Table 4 below.   
 
Uganda + 3 + + 1 + + + + +  
Southern Africa 
Madagascar 10 9 13 0 0 8 8 8 10 7  
Malawi 1 1 1 4 5 3 0 6 0 0  
Mozambique 4 14 7 7 4 15 7 11 8 10  
South Africa 161 96 60 102 91 77 59 43 25 14  
Zambia 0 80 90 182 291 237 0 162 181 170  
 
 
Table 4: Number of Bovine Anaplasmosis outbreaks reported to the AU-IBAR from 2005 to 2015 (numbers 
given only for the target countries). Source: AU-IBAR Year Books. 
 
Country 2005* 2006** 2007 2008 2009 2010 2011 2012 2013 2014 2015 
West Africa 
Senegal    1        
East Africa 
Kenya   31 57 + + 88 76 11 9  
Rwanda            
Tanzania   441 + + + 38 20 31 47  
Uganda    10 10 35   5 2  
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Prevalence data by country: 
The information below has been obtained from PubMed and internet engine search.  The information by 
country is extremely limited, as it tends to focus on the outbreaks, and very little countrywide surveys are 




• Although Bovine Anaplasmosis and A. marginale have been reported to be prevalent in Bangladesh since 
1976, with prevalence reaching 70% in certain districts [4], reporting to the OIE has been limited 
• In the study conducted by Belal et al. [4] in the Sirajganj District, which is the most important dairy belt 
area of Bangladesh with a high density of cattle population, they found an overall prevalence of 25.82%, 
with prevalence in older animals reaching 34.19%.   
  
India 
• Bovine anaplasmosis is recognised as one of the most economically important disease of livestock in 
India, ranking in the top 10 most important livestock diseases in the country in 2010 [11]. 
• Clinical anaplasmosis was first recorded in Indian cattle from the State of Odisha. Subsequently, A. 
marginale infection was detected in livestock of Uttar Pradesh, Punjab, Haryana, Tamil Nadu, Karnataka, 
Jammu and from parts of north and central India. In recent times, anaplasmosis has been recorded in 
Jammu, Karnataka, Haryana and Tamil Nadu. 
Southern Africa 
Madagascar   1 + + + 18     
Malawi   1  +   7    
Mozambique   5 15 3 12 7 2 11 5  
South Africa   60 102 35 81  55 26 15  
Zambia   90 + 48 2  43 174 122  
 
*AU-IBAR didn’t start yet producing data for bovine anaplasmosis 
**No individual country report available; 7 countries reported to a total of 334 outbreaks 
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• Reporting to the OIE has covered the following areas: 
o Goa 





o Uttar Pradesh 
o West Bengal 
o Punjab 
• In a study published by Ashuma et al. (2013) a 37.5% more prevalence of A. marginale was recorded by 
PCR method in dairy animals of Punjab  
• It can be concluded that bovine anaplasmosis is of high economic importance in India. 
 
Indonesia 
• As per their 2005 OIE report, typical clinical cases of anaplasmosis are found in cattle and some 
buffaloes in the provinces of West Sumatra, Riau, Jambi, West Java, Central Java, Yogyakarta, East Java, 
South Kalimantan and Southeast Sulawesi. 768 cases were reported in 2005 
• Indonesia has been reporting bovine anaplasmosis during the past 10 years. 
• In a study on feeder cattle imported to Indonesia from Australia in order to increase local production 
and meet increasing demand, a prevalence of 60.3% was found in sampled cattle [41], although these 
animals did not show clinical disease  
 
Myanmar  
On OIE reports, the administrative regions of Yangon and Shan State are mentioned as having the disease. 
  
Nepal 
Although incidence is reported to the OIE, no prevalence data could be found 
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• Based on OIE reports, the disease has been suspected over the 10 year period covered, but never 
reported 
• In a study on dairy cattle around Hanoi, northern Vietnam, blood samples were examined with 
commercially available Svanovir®Elisa's for the presence of A. marginale specific antibodies, and a 




No data could be found  
 
Cote d’Ivoire 
No data could be found 
 
Ethiopia 
• A study on 384 blood samples collected from ruminants present in Debre-Zeit town and surrounding 
peasant associated areas found a prevalence of 6.3% to Anaplasmas, of which 2.1% was A. marginale [38] 
• In a survey reported by ILRI, not dated 
(https://www.ilri.org/InfoServ/Webpub/fulldocs/Dolanm/ethiopia.htm), 2434 blood smears and 242 
serum samples were collected from 21 state and private dairy farms to determine the prevalence of tick-
borne infections, mainly in dairy cattle. Over 90% of sera tested were positive for A. marginale. 
 
Kenya 
• A recent study conducted in intensively studied cohort of indigenous calves in western Kenya where 
calves were recruited close to birth and monitored for the presence of infectious disease for up to 51 
weeks, using the reverse line blot hybridization assay on the remaining 453 animals, showed a 
prevalence of 42.7%, part of co-infection with other haemoparasites [29] 
• In a paper published in 2014 by the same group where the same calves were monitored for 
seroconversion,  it was shown that 50% of the final 453 animals seroconverted to A. marginale, when 
tested with the species-specific antibody-capture ELISAs [16] 
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• The high seroconversion rate and high prevalence noted in this important study denote the significant 
importance of A. marginale in Kenya, though the study focused on Western Kenya. 
• In an earlier study in wildlife and domestic species in wildlife-livestock interface areas of Kenya by [27], 
where a competition inhibition ELISA assays was used on samples from different game animals, the 
prevalence detected is summarised in Table 5 below.  
 
 
• In another study, a cross-sectional survey conducted by Gachohi and associates on haemoparasitic 
diseases of small holders in Kenya have mentioned the prevalence of Anaplasma marginale to be 52-
64% (Gachohi et al., 2010)  
 
Madagascar 
Although the disease is known to occur and reports are made to the OIE, no prevalence studies could be found. 
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Although the disease is known to occur and reports are made to the OIE, no prevalence studies could be found. 
 
Mali 
No information available. 
 
Mozambique 
• In a serological survey based on card agglutination test for A. marginale, conducted on 478 communal 
calves (4 to 15 months old) of the north western province of Tete, Mozambique, a prevalence of 63% 
was determined, ranging from 34.4% in one of the 6 districts to 87.3% in another [1] 
• Mozambique has been reporting bovine anaplasmosis regularly to the OIE and the AU-IBAR. 
 
Rwanda 
Although no specific studies could be found, bovine anaplasmosis is highly prevalent in Rwanda, based on 
reports to the OIE and on high occurrence of vector ticks the prevalence [31]. 
 
Senegal 
Although recognised to be present, no recent literature on bovine anaplasmosis in Senegal could be found. 
 
South Africa 
• There are several reports on the prevalence and occurrence of bovine anaplasmosis in South Africa. 
• A 2007 study reported by Mtshali [25] conducted in two regions of the Free State Province, a prevalence 
44% to 98%, similar in both regions, was found. 
• In another study reported by Mutshembele et al. [26], using aMSP1a PCR on 250 blood samples collected 
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• A cross-sectional serological survey of A. marginale conducted on 200 randomly selected smallholder 
farms in each of the Tanga and Iringa Regions of Tanzania, Swai et al. [40] assessed antibodies against A. 
marginale in sera from dairy cattle of all ages, sexes and breeds by ELISA. Antibodies to A. marginale 
were present in cattle throughout the study areas and the overall prevalence was 20% for Tanga and 
37% for Iringa. 




• A recent review by Mikael Palmfjord [23] indicates that in serological analyses of Anaplasma spp. in Uganda, 
sero-prevalences have ranged between 30-60 % (Table 6). He also mentions that another recently published 
study in Central and Western Uganda showed an overall microscopic prevalence of Anaplasma spp. of 14.4 %.  
 
Zambia 
• Jongejan et al. [15] found prevalence by CAT on samples collected throughout Zambia of 14.7% to 38.6%. 
By retesting 200 of the sera by ELISA the sero-prevalence was 1.5 to 2.3 times greater with ELISA than 
with the CAT. 
• In a 2009 PhD thesis by Simmunza [39] which included an Epidemiological analysis of tick-transmitted 
diseases of cattle in Central, Lusaka and Eastern Zambia, a total of 637 cattle were sampled and of these, 
422 were from Eastern Province, 151 from Central province. The table below provides a summary of 
prevalence determined using the 16S rRNA gene semi-nested PCR assays. Prevalence of Anaplasma spp., 
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Economic and Social Impacts at Global 







Throughout the tropical and subtropical areas of the world where anaplasmosis occurs, the disease is a major 
constraint to the cattle production in many countries. 
For example, in a 2003 publication, Kocan et al. cited annual losses in beef cattle in the United States as a result 
of anaplasmosis morbidity and mortality being estimated to be over $300 million per year. In the same paper, 
she mentions that in Latin America those losses were calculated to be approximately $800 million per year.  
Most economic impact studies covering bovine Anaplasmosis are conducted for all Tick-borne parasitic diseases. 
The study and report by Minjaw B et al., 2003 provides more information on the impact of ticks and tick-borne 
diseases on the livelihoods of small-scale and marginal livestock owners in India and eastern and southern 
Africa. 
A more recent report by Kivaria, 2006 in Tanzania, estimated the direct annual losses due to bovine 
anaplasmosis to amount to 47.3 million USD [17]. 
In India, bovine anaplasmosis is considered as one of the top 10 diseases of cattle. [11]  
Based on the work by Minjaw et al. [24], the number of animals at risk of bovine anaplasmosis based on the 
presence of the vectors has been estimated to be very high, over 114 million, in Sub-Saharan Africa, as 
illustrated in Figure 5.  This risk map was developed through a DFID project, in 2003, conducted jointly with ILRI.   
To create a disease risk map, the predicted distribution maps of all of the ticks responsible for the transmission 
of bovine anaplasmosis were combined. The resulting map, in Figure 5 excludes any predictions of habitat 
suitability (at all levels of probability) that were more than 3 degrees from an observed value. In this way, the 
actual risk of disease was determined by the observed presence of the vectors, and areas in which the habitat 
might be suitable but the vectors absent were excluded.  
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Figure 5: Distribution of bovine anaplasmosis risk based on probability of vector presence [24] 
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Control of Bovine Anaplasmosis varies according to regions and, depending on whether outbreaks are occurring 
in a known enzootic area, or as focal isolated events in non-enzootic regions, control measures that could be 
implemented will consist of the following approaches or their combination:  
• Maintaining an A. marginale-free herd 
• Vaccination 
• Tick control 
• Treatment with tetracycline during acute disease  
• Administration of low-level tetracycline for prevention of clinical disease  
 
Tick control 
Arthropod control is not practical in many areas and may only partially prevent against A. marginale 
transmission, which occurs both by mechanical transmission of infected blood via insects and fomites and by 
biological transmission via ticks. 
In regions where anaplasmosis is endemic, such as in Sub-Saharan Africa, its eradication followed by the 
implementation and long-term maintenance of strict tick control programmes (to control it and other endemic 
tick-borne diseases, such as heartwater, babesiosis and anaplasmosis) is not generally recommended. Stringent 
tick control would render the cattle population susceptible to several other tick-borne diseases with potentially 
catastrophic consequences. 
 
In addition to problem associated to tick resistance to acaricides, a further complicating factor in Southern and 
Eastern Africa is that populations of wild ruminants sustain tick populations and that some are probably 
reservoir hosts to A. marginale.  
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For these reasons it is generally recommended in Southern and Eastern Africa, that a stable disease situation be 
pursued by allowing natural exposure of calves to tick-borne diseases, including anaplasmosis, during the period 
when they are naturally resistant or protected by passively acquired maternal antibody. 
 
Chemotherapy 
The treatment of clinical anaplasmosis in cattle requires, firstly, the suppression or elimination of the parasite 
(specific treatment) and, secondly, the alleviation or prevention of secondary complications and the hastening of 
recovery (symptomatic or supportive treatment). Different products are used as summarised in Table 9 below. 
Tetracycline antibiotics are by far the predominant treatment for bovine anaplasmosis. Repeated doses of 
tetracycline can eliminate persistent A. marginale infections, although complete elimination is not always 
achieved.  
Imidocarb and Enrofloxacin have also shown good results, but they are not commonly used [35]. 
Tetracycline is most effective in the earlier stages of the disease: it can be difficult to catch the disease early 
enough in range cattle [20]. Therefore, it is sometimes used prophylactically, particularly in the US [20]. Such 
frequent use of antibiotics has the potential to cause selection of resistant strains, but to date this has not been 
reported as a problem. 
Tetracycline is also used in some regions in the “Infection-treatment” method. This procedure involves 
inoculation of cattle with A. marginale-infected erythrocytes followed by treatment with low doses of 
tetracycline drugs during the initial appearance of patent infection. The cattle then become persistently infected 
without experiencing acute anaplasmosis and are subsequently immune to challenge exposure with the same or 
different isolates. This approach requires careful monitoring to ensure acute disease does not develop, and so 
can be unsuitable for large herds of cattle.  
While antibiotic treatment can clear and sterilise the infection, there are a number of concerns worth noting; 
• Cattle in which infections have been eliminated shortly after primary infection exhibit no residual 
immunity upon challenge with A. marginale. In contrast, cattle cleared of carrier infections are 
susceptible to reinfection but show resistance to clinical anaplasmosis for periods ranging from a few to 
30 months following parasite elimination [35] 
• The withholding period in antibiotic-treated cattle before they can be used for meat or milk can be a 
problem  for farmers, particularly with long-lasting oxytetracycline preparations 
• While antibiotic resistance for Anaplasmosis has not been described, the frequent use of antibiotics in 
Africa, where substandard and counterfeit  drugs are commonly found in many countries, could impact 
negatively on other concurrent or secondary infections   
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Since the first description of A. marginale and A. centrale by Arnold Theiler in 1910 and the subsequent 
development of an A. central based blood vaccine, there has been no new effective alternative widely used to 
immunise cattle, besides inactivated vaccine used in limited fashion in the USA. Vaccination has been an 
economical and effective way to control bovine anaplasmosis wherever it has been applied. Vaccines for the 
control of anaplasmosis can be divided into two major types: live and killed vaccines. Both types of vaccines rely 
on the use of A. marginale or A. centrale from infected bovine erythrocytes as the antigen source.  
They both induce protective immunity that mutes or prevents clinical disease, but neither type prevents cattle 
from becoming persistently infected with A. marginale. 
 
Killed vaccine 
Killed bovine anaplasmosis vaccines are almost exclusively made and used in the USA. Developed in the 1960s, 
and marketed commercially until 1999 when most of them got withdrawn, they have advantages and 
disadvantages summarised in Table 8 below. 
 
Table 8: Advantages and disadvantages of the killed bovine anaplasmosis vaccines 
 
ADVANTAGES DISADVANTAGES 
• They have low risk of contamination with 
undesirable infectious agents,  
• Can be inexpensively stored and  
• Generally cause minimal post-inoculation reactions. 
• The need for yearly boosters,  
• High cost of purification of A. marginale from 
erythrocytes and  
• Lack of cross protection among isolates from widely 
separated geographic areas.  
• The protective immunity afforded is usually less than 




Two commercial bovine anaplasmosis killed vaccines were manufactured and commercialised in the US by Fort 
Dodge (Fort Dodge Laboratories, Fort Dodge, Iowa) and Mallinkrodt (later Schering-Plough) under the 
commercial name “Anaplaz®”, and “Plazvax®” respectively. They both got discontinued in 1999. 
Currently the only manufacturer, who has received USDA approval to commercialise a killed A. marginale 
vaccine is the US is the University Products LLC of Baton Rouge. 
(http://www.anaplasmosis.com/aboutus.html).   
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Live vaccines have been used against bovine anaplasmosis for over a century, from the time Sir Arnold Theiler 
first identified A. marginale and A. centrale. They are still today the most widely used type [19]. As live vaccines, 
most of which are based on A. centrale, lead to a persistent infection in immunized cattle, they provide with 
lifelong protection against clinical and severe disease. They produce a stronger immune response than killed 
vaccines, with the generation of antigenic variants during persistent infection leading to a broader immune 
response [34]. This type of vaccine is further discussed in the following section. 
Research toward a better understanding of the A. marginale organism, its infection, and host pathogen 
interaction have led to the development of several vaccine strategies and experimental candidates, none of 
which have gone beyond proof of concept stage.   
 





Disease situation and government policies by country 
Tables 10 and 11 below have been completed with the information received so far from the questionnaires sent 
to the DG and DVS of the countries of interest.  This information will be updated and completed once the results 
from the different countries is received. The list of the respondents can be seen in Annex 2.  
Table 10 covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or control 
programs, and the treatment situation.  Table 11 refers to the vaccination situation. 
The definitions that were given to the respondents are: 
Vaccine Dosage, Administration and Withdrawal 
Times
Countries Life Stages Adverse Affects
Anaplasma 
centrale
Prepared from blood of infected 
splenectomized calves. Chilled or Frozen 
forms. Administered as a single 
vaccination.
South Africa, Australia, Israel, 
Argentina, Uruguay, 
All Stages Can cause severe clinical 
reactions. Risk of contamination 





2 doses 4 weeks apart with annual booster. 
Withdrawn in 1998.
USA All Stages May cause neonatal 











2 doses given 4 weeks apart, with yearly 
booster. Given subcutaneously. Vaccine 
does not prevent infection but aids in 
prevention or reduction in the severity.
USA All Stages
modified live ovine 
Anaplasma 
marginale vaccine
2 ml intramuscularly in a single dose. No 
longer available outside California, USA.
South America; Australia All Stages May have severe clinical 
reactions especially in cattle over 
2 years of age. Risk of 
contamination with pathogens 
unless high standards applied.
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1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely dissemination 
of information to those who need to know so that action can be taken.  
2Control: a programme which is approved, and managed or supervised by the Veterinary Authority of a country 
for the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that 
country, or within a zone or compartment of that country. 
 
Table 10: Official status, official programs for Bovine anaplasmosis in the countries of interest 






















Bangladesh      
India      
Indonesia      
Myanmar (Burma) No No No No Yes 
Nepal      
Vietnam      
AFRICA 
Burkina Faso      
Côte d'Ivoire (Ivory 
Coast) 
Yes Passive, but active 
if outbreaks 
No Yes When animals are 
sick 
Ethiopia      
Kenya Yes Yes No Yes Yes 
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Madagascar      
Malawi No No Yes Yes Yes 
Mali - - - - - 
Mozambique      
Rwanda       
Senegal      
South Africa      
Tanzania  No  Yes, passive Yes Yes Yes 
Uganda      
Zambia     ` 
 
 
Table 11: Official status, official programs for Bovine anaplasmosis in the countries of interest 
















Species vaccinated (cattle, 
sheep, goats, pigs, poultry) 
ASIA 
Bangladesh     
India     
Indonesia     
Myanmar (Burma) No - - - 
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Nepal     
Vietnam     
AFRICA 
Burkina Faso     
Côte d'Ivoire (Ivory 
Coast)  
No - - - 
Ethiopia     
Kenya N/A N/A N/A N/A 
Madagascar     
Malawi No N/A N/A N/A 
Mali N/A N/A N/A N/A 
Mozambique     
Rwanda     
Senegal     
South Africa     
Tanzania  No Not done Not done N/A 
Uganda     
Zambia     
 
-   : No information provided in the questionnaire. 
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Although several approaches have been tried to immunise cattle against anaplasmosis, the oldest and to date 
probably still the most effective and widely used method of prophylaxis against anaplasmosis is vaccination with 
Theiler’s A. centrale isolate, as blood vaccine [43]. However, A. centrale, although generally a mild pathogen, can 
cause severe clinical reactions following vaccination. 
At Onderstepoort veterinary Institute (OVI) where the South African vaccine antigen is produced, cattle born 
and raised under strict tick-free (quarantine) conditions and tested free from blood-transmissible pathogens are 
splenectomized prior to infection with the Onderstepoort A. centrale vaccine parasite. The intensity of the 
infections in the animals is measured and blood is collected in anticoagulant at the acute stage of infection with 
these parasites. The blood is then diluted to contain a standardized number of parasites per dose.  
OVI supplies bulk blood vaccine to Onderstepoort Biological Products (OBP) where the vaccine is bottled into 
five-dose containers, snap-frozen before storing in bulk liquid nitrogen containers. Frozen vaccines are produced 
in monovalent form. The vaccine is packed, and subjected to strict quality control testing before it is released for 
issue on demand. 
The challenges associated with the logistics of distributing the frozen blood vaccine from OVI/OBP have limited 
its distribution in certain parts of the country and prevented its commercialisation beyond South Africa. Sporadic 
limited sales are done outside South Africa, especially in other Southern African countries such as Zambia, 
Zimbabwe, Namibia and Mozambique on a limited scale (personal communication OBP Export sales manager).      
While the South African vaccine is supplied in a frozen form, Australia produces a Trivalent chilled vaccine 
(https://www.daf.qld.gov.au/__data/assets/pdf_file/0008/61388/Tick-Fever-A2-Trivalent-Tick-Fever-
Vaccine-Specifications.pdf ), which is distributed within the 4 days of its shelf life. 
Other countries that produce the frozen vaccines made of the A. centrale originating from the Theiler vaccine 
are Argentina, Uruguay and Israel. Malawi and Zimbabwe had produced the vaccine for a while and have 
discontinued since.    
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Table 12 below summarises the strength, weaknesses, threats and opportunities with the current bovine anaplasmosis 
blood vaccine used, both as a monovalent or a bivalent vaccine. 










• Cross protection to most 
A.marginale 
• Proven ability to be used in 
the control of bovine 
anaplasmosis. 
• Leads to high production of 
IgG, high cross-reactivity 
within that IgG response, a 
strong IgG2 bias, and high 
opsonophagocytic activity 
(Kenneil; 2015) 
• Limited efficacy 
• Very difficult to 
produce, relies on old 
technology 
• Difficult to validate 
production process in 
modern vaccinology 
(produced in cattle). 
• Production in live cattle 
carries the risk of 
transmission of other 
blood borne pathogens. 
• Cell culture to replace cattle;  
• Better understanding of 
mechanisms that make A. 
centrale better vaccine than 
attenuated A.marginale may lead 
to better alternatives. 
• Concerns on antibiotic resistance 
will lead to more reliance on 
vaccine, hence creating new 





Commercial vaccines manufactured in Africa and Asia  
 








Bovine Anaplasmosis | Monograph 09 






Table 13:  Characteristics of the BA vaccine produced by OBP (source: www.vetvac.org  ) 
 
Manufacturer  Onderstepoort Biological Products Ltd.  
Countries of 
distribution 
Namibia, South Africa  
For vaccination of 
the following animals 
Cattle 
 






Dosage (ml) 1 Route(s) of 
administration 
Intramuscular 
Use with pregnant 
animals 
Pregnant cows may abort and 
should therefore be vaccinated 
only after calving. 





Known side effects The anaplasmosis vaccine 
reactions usually set in from the 4th 
to the 6th week after inoculation 
and last for approximately 2 weeks. 
The peak of the reaction may be 
accompanied by fever (40 °C or 
higher) and symptoms such as 
poor appetite, decreased milk 









no Packaging Bottles of 5 doses 
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Commercial vaccines imported into Africa 
 
The information summarised in Table 14, is based on a questionnaire send to the Director of Veterinary Services 
office and regulators of the countries of interest.  Note that some vaccines might have been imported under DVS 
dispensation, and they are not necessary licensed in the country.  
Given the fact that no Asian countries vaccinate against Bovine anaplasmosis, neither do most African countries, 
there is very little imports of this vaccine 
Storage -70 ºC. May only be kept on dry ice 
or in liquid nitrogen (temperatures 
below -70°C). Vaccine which on 
receipt is completely thawed, is 
ineffective an 






Reg No. G1106 (Act 36/1947, 
South Africa), NSR 0569 (Namibia) 
Notes & comments In those areas of the country where anaplasmosis occurs, all calves should be vaccinated at 
approximately 6 months of age (between 3 and 9 months). Cattle should have developed 
immunity on average 2 months after vaccination.In anaplasmosis areas where vaccinated cattle 
are exposed to infected ticks, they will develop life-long immunity.  
 
 


























Bangladesh        
India        
Indonesia        
Myanmar 
(Burma) 
- - - - - - - 
Nepal        
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Vietnam        
AFRICA 
Burkina Faso        
Côte d'Ivoire 
(Ivory Coast) 
- - - - - - - 
Ethiopia        
Kenya - - - - - - - 
Madagascar        
Malawi N/A N/A N/A N/A N/A N/A N/A 
Mali N/A N/A N/A N/A N/A N/A N/A 
Mozambique        
Rwanda        
Senegal        
South Africa        
Tanzania  - - - - - - - 
Uganda - - - - - - - 
Zambia        
 
-   : No information provided in the questionnaire. 
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Table 15: Target Product Profile (TPP) Bovine Anaplasmosis vaccine – Proposal: 
 





Immunogen with protective 
antigens of A. marginale or A. 
centrale that protects against 
A.marginale infection 
Immunogen capable of providing full 
protection in cattle against A. marginale 
infection 
2 Indication for use For active immunization of cattle & 
water buffaloes 
For active immunization of cattle, water 
buffalos and all susceptible animals  
3 Recommended species 
 
Cattle, Water buffaloes All A. marginale susceptible livestock  
4 Recommended dose 
 
2 ml 1 ml 




vaccine) or ready to use solution 
(inactivated vaccine) 
Ready to use solution/suspension 
6 Route of administration 
 
intramuscular SC, Intramuscular or pour on 
7 Regimen - primary 
vaccination 
Single dose Single lifetime dose 
Bovine Anaplasmosis | Monograph 09 






8 Regimen - booster Single annual booster Lifelong immunity after primary 
vaccination 
9 Epidemiological relevance Protection against all geographically 
distinct strains of A.marginale  
Protection against RVF and prevention of 
virus transmission 
10 Recommended age at first 
vaccination 
Animals over 3 months: one 
injection 
 
From 1-2 months of age  
11 Onset of immunity 
 
2-3 weeks following primary 
vaccination 
One week following primary vaccination 
12 Duration of immunity 
 
At least 1 year 
 
Lifelong immunity 
13 Expected efficacy To prevent disease & prevent 
mortality. 
To prevent infection and transmission. No 
disease & no mortality in vaccinated 
animals after virulent challenge. 
14 Expected safety In animals under 6 months of age, a 
transient pyrexia reaction can occur.  
A transient nodular reaction of 
varying importance may appear at 
the injection site, it progressively 
disappears within 1 to 2 months.  
Only vaccinate pregnant animals on 
emergency. 
No post-vaccinal reactions at any age. Safe 
for pregnant animals.  
No carrier form in vaccinated animals 
15 Withdrawal period 
 
Nil Nil 
16 Special requirements for 
animals 
Do not vaccinate un-healthy animals Do not vaccinate un-healthy animals 
DIVA 
17 Special requirements for 
persons 
 None None 
18 Package size 
 
50 doses Multiple pack size from 10 doses 
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Overall conclusion for improved Bovine anaplasmosis control through vaccination 
• It is clear that bovine anaplasmosis is an economically important TBD in all the African and Asian 
countries targeted in the present report. In East Africa East Coast Fever (ECF) has such prominence as an 
important disease that other TBDs are overlooked despite their high prevalence. The longitudinal study 
described earlier, conducted in Kenya on a cohort of calves followed over a 51 weeks period has shown 
a high rate of A. marginale infection, demonstrating the importance of the disease in this East African 
country where more focus is put on ECF. Similarly, in South and South East Asia, bovine anaplasmosis 
has a high prevalence, being classified in country like India among the top livestock diseases.  
• Despite this, only South Africa has a vaccine which is used regularly. All other countries rely on 
chemotherapy, with its limitation and long term consequences. 
• Vaccination would still be the best way to control the disease, and should be expanded in other affected 
countries, especially on the African continent. One of the reasons is the fact that livestock keepers end 
up turning toward antibiotics, most of which are fake or substandard in many countries.  
• The current live Theiler A. centrale has serious limitations that would prevent its use in more countries. 
• With limited research and work toward the development of a vaccine over the past few years, by lack of 
funds, a new generation vaccine may be a long way away. There may be a possibility of evaluating in 
target animal the candidates selected by the Washington State University group. These candidate 
vaccines are likely to lead to a potentially very efficacious and safe vaccine.  
• The “quick win” would be the use of the newly established cell culture system for A.centrale vaccine 
strain developed at Pirbright, which could allow the production of a less risky cell-based vaccine. 
Additionally, work on lyophilisation of the vaccine could be pursued. A cell-based lyophilised bovine 
anaplasmosis vaccine would then have a major impact on in the control of bovine anaplasmosis.
19 Price to end user 
 
Not more than $0.50/dose $0.20/dose at end user  
20 Storage condition and 
shelf-life as packaged for 
sale 
12 months at 4-8° C   
 
 24 months 4-8° C and/or 48 hours at 30° C 
 
21 In-use stability 
 
1 hour 24 hours 
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ANNEX 1: Additional data on disease presence and 
incidence 
 
Reports to OIE on Bovine anaplasmosis: 
 
When different animal health statuses between domestic and wild animal population are provided, the box is 
split in two: the upper part for domestic animals, and the lower part for wild animals.  
Bovine anaplasmosis in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam 
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Bovine anaplasmosis in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal 
 
Bovine anaplasmosis in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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Bovine anaplasmosis in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
 
 
 
 
 
 
 
